Fatal Cerebral Venous Sinus Thrombosis Associated with the Factor V Leiden Mutation and the Use of Oral Contraceptives

Thromb Haemost 1995; 74(05): 1382
DOI: 10.1055/s-0038-1649947

Letter To The Editor

Schattauer GmbH Stuttgart

Françoise Bridey

¹Service d’Hématologie et d’lmmunologie Biologiques et INSERM U 294, Paris, France

,

Michel Wolff

²Clinique de Réanimation des Maladies Infectieuse, Paris, France

,

Jean Pierre Laissy

³Service de Radiologie Viscérale, Hôpital Bichat-Claude Bernard, Paris, France

,

Véronique Morin

¹Service d’Hématologie et d’lmmunologie Biologiques et INSERM U 294, Paris, France

,

Martine Lefebvre

¹Service d’Hématologie et d’lmmunologie Biologiques et INSERM U 294, Paris, France

,

Dominique de Prost

¹Service d’Hématologie et d’lmmunologie Biologiques et INSERM U 294, Paris, France

References
1 Vandenbroucke JP, Koster T, Briët E, Reitsma PH, Bertina RM, Rosendaal FR. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet 1994; 344: 1453-1457
2 Gandrille S, Alhenc-Gelas M, Aiach M. A rapid screening method for the factor V Arg 506 Gln mutation. Blood Coag Fibrinol 1995; 6: 245-248
3 Bertina RM, Koeleman BP C, Koster T, Rosendaal RF, Dirven RJ, de Ronde H, van der Velden PA, Reitsma PH. Mutation in blood coagulation Factor V associated with resistance to activated protein C. Nature 1994; 369: 64-67
4 Emmerich J, Poirier O, Evans A, Marques-Vidal P, Arveiler D, Luc G, Aiach M, Cambien F. Myocardial infarction, Arg 506 to Gln factor V mutation, and activated protein C resistance. Lancet 1995; 345: 321